Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mannatide is an orally active glycopeptide complex derived from the cell wall of *Saccharomyces cerevisiae* (yeast). It functions as a non-specific immunomodulator, primarily by enhancing the phagocytic activity of macrophages and stimulating the production of various cytokines. In clinical practice, particularly in China, it is frequently utilized as an adjuvant therapy to mitigate the myelosuppressive effects of chemotherapy, such as leukopenia, and to bolster the host's immune response against tumors. It is currently being investigated in combination with checkpoint inhibitors like tislelizumab and chemotherapy regimens (e.g., CAPOX) for the treatment of advanced gastric and gastroesophageal junction adenocarcinomas to potentially modulate the tumor immune microenvironment and improve clinical outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mannatide.